清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study

医学 安慰剂 化疗 内科学 肿瘤科 性能状态 卡培他滨 中期分析 胃肠病学 外科 临床试验 癌症 病理 结直肠癌 替代医学
作者
Jianming Xu,Ken Kato,Éric Raymond,Richard A Hubner,Yongqian Shu,Yueyin Pan,Sook Ryun Park,Lu Ping,Yi Jiang,Jingdong Zhang,Xiaohong Wu,Yuanhu Yao,Lin Shen,Takashi Kojima,Evgeny Gotovkin,Ryu Ishihara,Lucjan Stanislaw Wyrwicz,Eric Van Cutsem,Paula Jiménez‐Fonseca,Chen‐Yuan Lin
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:24 (5): 483-495 被引量:377
标识
DOI:10.1016/s1470-2045(23)00108-0
摘要

Summary

Background

The options for first-line treatment of advanced oesophageal squamous cell carcinoma are scarce, and the outcomes remain poor. The anti-PD-1 antibody, tislelizumab, has shown antitumour activity in previously treated patients with advanced oesophageal squamous cell carcinoma. We report interim analysis results from the RATIONALE-306 study, which aimed to assess tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma.

Methods

This global, randomised, double-blind, parallel-arm, placebo-controlled, phase 3 study was conducted at 162 medical centres across Asia, Europe, Oceania, and North America. Patients (aged ≥18 years) with unresectable, locally advanced, recurrent or metastatic oesophageal squamous cell carcinoma (regardless of PD-L1 expression), Eastern Cooperative Oncology Group performance status of 0–1, and measurable or evaluable disease per Response Evaluation Criteria in Solid Tumours (version 1.1) were recruited. Patients were randomly assigned (1:1), using permuted block randomisation (block size of four) and stratified by investigator-chosen chemotherapy, region, and previous definitive therapy, to tislelizumab 200 mg or placebo intravenously every 3 weeks on day 1, together with an investigator-chosen chemotherapy doublet, comprising a platinum agent (cisplatin 60–80 mg/m2 intravenously on day 1 or oxaliplatin 130 mg/m2 intravenously on day 1) plus a fluoropyrimidine (fluorouracil [750–800 mg/m2 intravenously on days 1–5] or capecitabine [1000 mg/m2 orally twice daily on days 1–14]) or paclitaxel (175 mg/m2 intravenously on day 1). Treatment was continued until disease progression or unacceptable toxicity. Investigators, patients, and sponsor staff or designees were masked to treatment. The primary endpoint was overall survival. The efficacy analysis was done in the intention-to-treat population (ie, all randomly assigned patients) and safety was assessed in all patients who received at least one dose of study treatment. The trial is registered with ClinicalTrials.gov, NCT03783442.

Findings

Between Dec 12, 2018, and Nov 24, 2020, 869 patients were screened, of whom 649 were randomly assigned to tislelizumab plus chemotherapy (n=326) or placebo plus chemotherapy (n=323). Median age was 64·0 years (IQR 59·0–69·0), 563 (87%) of 649 participants were male, 86 (13%) were female, 486 (75%) were Asian, and 155 (24%) were White. 324 (99%) of 326 patients in the tislelizumab group and 321 (99%) of 323 in the placebo group received at least one dose of the study drug. As of data cutoff (Feb 28, 2022), median follow-up was 16·3 months (IQR 8·6–21·8) in the tislelizumab group and 9·8 months (IQR 5·8–19·0) in the placebo group, and 196 (60%) of 326 patients in the tislelizumab group versus 226 (70%) of 323 in the placebo group had died. Median overall survival in the tislelizumab group was 17·2 months (95% CI 15·8–20·1) and in the placebo group was 10·6 months (9·3–12·1; stratified hazard ratio 0·66 [95% CI 0·54–0·80]; one-sided p<0·0001). 313 (97%) of 324 patients in the tislelizumab group and 309 (96%) of 321 in the placebo group had treatment-related treatment-emergent adverse events. The most common grade 3 or 4 treatment-related treatment-emergent adverse events were decreased neutrophil count (99 [31%] in the tislelizumab group vs 105 [33%] in the placebo group), decreased white blood cell count (35 [11%] vs 50 [16%]), and anaemia (47 [15%] vs 41 [13%]). Six deaths in the tislelizumab group (gastrointestinal and upper gastrointestinal haemorrhage [n=2], myocarditis [n=1], pulmonary tuberculosis [n=1], electrolyte imbalance [n=1], and respiratory failure [n=1]) and four deaths in the placebo group (pneumonia [n=1], septic shock [n=1], and unspecified death [n=2]) were determined to be treatment-related.

Interpretation

Tislelizumab plus chemotherapy as a first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma provided superior overall survival with a manageable safety profile versus placebo plus chemotherapy. Given that the interim analysis met its superiority boundary for the primary endpoint, as confirmed by the independent data monitoring committee, this Article represents the primary study analysis.

Funding

BeiGene.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
活泼溪流完成签到 ,获得积分10
1秒前
余又完成签到 ,获得积分10
1秒前
工艺纯化小天才完成签到 ,获得积分10
17秒前
在路上完成签到 ,获得积分10
18秒前
feiyafei完成签到 ,获得积分10
21秒前
Yi完成签到,获得积分0
29秒前
zjz完成签到 ,获得积分10
31秒前
小西西完成签到,获得积分10
34秒前
今后的应助被阿亮采纳,获得10
41秒前
44秒前
Arvin发布了新的文献求助10
47秒前
詹姆斯哈登完成签到,获得积分0
51秒前
Miya完成签到,获得积分10
53秒前
xurui_s完成签到 ,获得积分10
57秒前
传奇3的应助被竹捷采纳,获得10
1分钟前
烂漫的淇完成签到 ,获得积分10
1分钟前
1分钟前
竹捷发布了新的文献求助10
1分钟前
1分钟前
cczzhh发布了新的文献求助10
1分钟前
昭荃完成签到 ,获得积分0
1分钟前
Lina完成签到 ,获得积分10
1分钟前
回家睡觉完成签到,获得积分10
1分钟前
温馨家园完成签到 ,获得积分0
1分钟前
英姑的应助被科研通管家采纳,获得30
1分钟前
李煜琛完成签到 ,获得积分10
2分钟前
hj完成签到 ,获得积分10
2分钟前
kk完成签到,获得积分10
2分钟前
luoqin完成签到 ,获得积分10
2分钟前
姚芭蕉完成签到 ,获得积分0
3分钟前
my完成签到 ,获得积分10
3分钟前
朴实惜寒完成签到,获得积分10
3分钟前
3分钟前
朴实雨竹完成签到,获得积分10
3分钟前
阿巴完成签到,获得积分10
3分钟前
8D完成签到 ,获得积分10
3分钟前
无限的画板完成签到 ,获得积分10
3分钟前
3分钟前
我爱木棉完成签到 ,获得积分10
3分钟前
颜三路吴彦祖完成签到 ,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195261
求助须知:如何正确求助?哪些是违规求助? 9580992
关于积分的说明 21873160
捐赠科研通 7795344
什么是DOI,文献DOI怎么找? 3437973
关于科研通互助平台的介绍 2561284
邀请新用户注册赠送积分活动 2484713